RxDoctor Payments Data

William Fleming, MD

Neurology · Houston, TXNPI 1255384574

Payments from drug & device makers

$27,274in general payments, 2019–2025

Across 812 payments — averaging $33.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$12K
  • Argenx US, Inc.$1K
  • AbbVie$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • Novartis$1K
  • AstraZeneca$861
  • plus $10K from 52 others

What the payments were for

  • Consulting fees$3,22212%
  • Speaking & faculty fees$8,82632%
  • Food & beverage$15,12655%
  • Education$1000%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen63$11,963
Argenx US, Inc.6$1,343
AbbVie(2 entities)71$1,189
Supernus Pharmaceuticals, Inc.43$1,132
Novartis70$1,015
AstraZeneca(2 entities)66$861
UCB, Inc.29$767
Sanofi30$721
Teva Pharmaceuticals USA, Inc.36$625
Acadia Pharmaceuticals Inc38$602
Genentech USA, Inc.34$532
Eisai Inc.33$514
Amgen(2 entities)18$477
SK Life Science, Inc.22$466
Adamas Pharmaceuticals, Inc.18$388
Abbott19$379
CSL Behring14$332
Pfizer15$315
Boston Scientific8$239
Sunovion Pharmaceuticals Inc.14$194
TG Therapeutics, Inc.7$190
Ironshore Pharmaceuticals Inc.9$187
Kyowa Kirin, Inc.8$173
Lilly USA, LLC11$168
Lundbeck LLC8$158
Tris Pharma Inc8$158
Neos Therapeutics, LP10$157
Arbor Pharmaceuticals, Inc.11$153
Biohaven Pharmaceutical Holding Company Ltd.6$142
EMD Serono, Inc.8$140
Corium, LLC6$139
Aquestive Therapeutics, Inc.8$132
Neurocrine Biosciences, Inc.6$126
Amneal Pharmaceuticals LLC9$122
Johnson & Johnson6$110
Sumitomo Pharma America, Inc.6$103
Otsuka America Pharmaceutical, Inc.4$101
Sanofi-aventis U.S. LLC2$100
ANI Pharmaceuticals, Inc.3$90
Biohaven Pharmaceuticals, Inc.3$85
Shire North American Group Inc3$62
Livanova USA, Inc.2$44
Takeda Pharmaceuticals U.S.A., Inc.2$40
Assertio Therapeutics, Inc.2$39
Grifols USA, LLC2$38
Upsher-smith Laboratories LLC2$31
MDD US Operations, LLC2$30
E.r. Squibb & Sons, L.L.C.1$24
Greenwich Biosciences, Inc.1$22
Jazz Pharmaceuticals Inc.1$20
Bausch Health US, LLC1$20
Avion Pharmaceuticals1$18
Acorda Therapeutics, Inc1$18
Avanir Pharmaceuticals, Inc.1$18
Novo Nordisk1$17
Medtronic1$16
Tanabe Pharma America, Inc.1$14
Vanda Pharmaceuticals Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,274 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$191,152
Medicare patients
44
Services billed
2,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4641$130,572
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5030$121,052
Avonex Pen (4 Pack)Interferon Beta-1a13$105,732
NamzaricMemantine Hcl/Donepezil Hcl43$55,359
KeppraLevetiracetam15$29,600
UbrelvyUbrogepant14$22,079
Rasagiline Mesylate41$9,125
Dimethyl Fumarate11$3,271
Levetiracetam96$3,201
Gabapentin74$2,066
Pregabalin66$1,653
Carbamazepine16$1,592
Lacosamide15$1,506
Butorphanol Tartrate11$1,427
Primidone44$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$38$130,57241 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$40$121,05230 claims
AbbVieNamzaric, Ubrelvy$1,189$77,43857 claims
Upsher-smith Laboratories LLCTopiramate$31$57716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →